Metastatic pancreatic cancer (mPC) and its treatments signifcantly impact health-related quality of life (HRQoL). POLO, a randomized, double-blind, placebo-controlled phase 3 trial evaluated the efcacy of olaparib as maintenance therapy in germline BRCA mutated mPC patients who had not progressed during ≥16weeks of frst-line platinum-based chemotherapy. HRQoL was assessed using the EORTC QLQ-C30. |